The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.
Swain
S M
SM
National Institutes of Health, Department of Health and Human Services, 8901 Wisconsin Avenue, Building 8, Room 5101, Bethesda, MD 20889-5105, USA. swains@mail.nih.gov
Vici
P
P
D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D011929:Razoxane / Q000008:administration & dosage / Q000627:therapeutic use*
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D002316:Cardiotonic Agents; D011929:Razoxane